UNSPSC 51286900: Antibacterial quinoxalines

This classification denotes antibacterials made of benzopyrazines (benzene + pyrazine).

UNSPSC 51286900 Antibacterial quinoxalines is a Class code that in recent state and local procurement activity does not represent the scope being solicited. The source shows four recent opportunities tagged to this code, but none involves antibacterial quinoxalines or related antimicrobial compounds. Instead, the opportunities reflect naloxone and drug deactivation systems; therapeutic pharmacy initiatives and prescription fulfillment; medical and first aid supplies for emergency response; and generic multi-source pharmaceuticals and OTC products distributed through wholesalers. The mismatch between the code's nominal scope and the actual work being procured suggests either tagging error or a significant divergence between the UNSPSC taxonomy and state and local procurement practice in this domain. No recent opportunities directly support activity under the code's stated commodity line.

The issuing bodies span state health and human services commissions (Texas HHS), county health systems (Seminole County, Florida), city fire departments (Tampa Fire Department), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, which includes Oregon participants). Geographic activity appears concentrated in Florida, Texas, Minnesota, and Oregon based on the four identified records. Representative recent opportunities include Seminole County's IFB60459723LAS for naloxone and drug deactivation systems (IFB, due July 26, 2023, for 1,900 units of naloxone and 800 deactivation systems annually); the City of Tampa's ITB 26P00145 for medical and first aid supplies for the Fire Department Rescue Division (sealed bid, due March 13, 2026, estimated contract value $700,000.00, with SLBE set-aside and 5% discount); the Texas HHS Commission's RFI HHS0017013 for direct-to-manufacturer prescription capabilities (RFI, due April 3, 2026, exploratory market intelligence phase); and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (RFP, due March 26, 2026, for distribution effective July 1, 2026). The code shows little relevant recent activity aligned with its stated commodity scope.